Company Overview of Oxford BioTherapeutics Limited
Oxford BioTherapeutics Limited is engaged in the development of antibody-based cancer drugs for the treatment of cancer. It offers therapeutic antibodies and diagnostics. The company also provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies. It has strategic partnerships with Seattle Genetics Inc., Medarex Inc., Biosite Inc., Amgen Inc., and GlaxoSmithKline; and a strategic alliance with A. Menarini Industrie Farmaceutiche Riunite Srl. Oxford BioTherapeutics Limited was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Limited. in December 2008. The company was incorporated in 2003 and ...
94a Milton Park
Oxon, OX14 4RY
Founded in 2003
Key Executives for Oxford BioTherapeutics Limited
Founder, Chief Executive Officer and Director
Chief Operations Officer and Executive Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Head of Clinical Development
Compensation as of Fiscal Year 2014.
Oxford BioTherapeutics Limited Key Developments
Oxford BioTherapeutics Limited Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 11:00 AM
Feb 23 15
Oxford BioTherapeutics Limited Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-02-2015 11:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States.
Oxford BioTherapeutics Limited Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM
Feb 18 15
Oxford BioTherapeutics Limited Presents at 8th Annual EUROPEAN LIFE SCIENCE CEO FORUM & EXHIBITION, Mar-03-2015 12:15 PM. Venue: Hilton, Zurich Airport Hotel, Hohenbuehlstrasse 10, Opfikon-Glattbrugg 8152 Zurich, Zurich, Switzerland. Speakers: Esteban Pombo-Villar, Chief Operations Officer and Executive Director.
Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim
Jan 20 15
Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration. The target was discovered using Oxford BioTherapeutics' proprietary OGAP® system. This represents the first option exercised under the companies' oncology target discovery and validation collaboration established in 2013. Under the terms of the agreement, Boehringer Ingelheim will be responsible for the future development and commercialization of antibody products to the target. Oxford BioTherapeutics will receive development and regulatory milestone payments, and royalties on any future product sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries